26.07.19: Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in EuropeRecommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe with a tumor-agnostic indication / CHMP opinion is based on pooled data showing that larotrectinib provides high and durable responses in adult and pediatric patients with TRK fusion cancer, including CNS tumors / Larotrectinib showed a favorable safety profile, with the majority of adverse events being grade 1 or 2 / Final decision from the European Commission is anticipated within the next monthsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news